Cancer Family
Hematopoietic and Lymphoid Cell Neoplasm
CI-CAN-00000023Explore in graph →
HematologicNon-malignant4,231 active trials98 approved drugs1,009 evidence items
Loading cancer entity…
Cancer Family
CI-CAN-00000023Explore in graph →
Clinical trials
18,680 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT03600155 | Nivolumab and Ipilimumab After Donor Stem Cell Transplant in Treating Patients With High Risk Refractory or Relapsed Acute Myeloid Leukemia or Myelodysplastic Syndrome | completed | Phase 1 | 29 | M.D. Anderson Cancer CenterOTHER | 1 | May 15, 2026 | clinicaltrials |
| NCT03900949 | Gentuzumab Ozogamicin and Midostaurin Combination With Standard Cytarabine and Danunorubi Midostaurin as a Novel Approach to Treating Patients With Newly Diagnosed FLT-3 Mutated Acute Myeloid Leukemia | completed | Phase 1 | 21 | Uma BorateOTHER | 1 |
| May 15, 2026 |
| clinicaltrials |
| NCT05665374 | Calquence CLL 1L Japan PMS _ Japan Post-Marketing Surveillance (PMS) Study | completed | — | 67 | AstraZenecaINDUSTRY | 1 | May 15, 2026 | clinicaltrials |
| NCT06790420 | RITUXIMAB BS Intravenous Infusion 100mg・500mg [Pfizer] Post-marketing Database Study | completed | — | 2,703 | PfizerINDUSTRY | 1 | May 15, 2026 | clinicaltrials |
| NCT01053949 | IFM2009-02-Pomalidomide and Dexamethasone Phase 2 Myeloma(IFM2009-02) | completed | Phase 2 | 84 | University Hospital, LilleOTHER | 1 | May 14, 2026 | clinicaltrials |
| NCT01222286 | Study on the Anti-tumor Activity, Safety and Pharmacology of IPH2101 in Patients With Smoldering Multiple Myeloma(KIRMONO) | completed | Phase 2 | 30 | Innate PharmaINDUSTRY | 1 | May 14, 2026 | clinicaltrials |
| NCT04936776 | Pediatric Vaccinations | completed | — | 1,034 | NYU Langone HealthOTHER | 1 | May 14, 2026 | clinicaltrials |
| NCT05774990 | Study Protocol: Study on Incidence and Risk Factors of Mold Infections in Children During Leukemia Treatment | completed | — | 621 | University of Southern DenmarkOTHER | 1 | May 14, 2026 | clinicaltrials |
| NCT06449924 | An Endotracheal Tube Inserted to the Level of the Hypopharynx | completed | — | 85 | American University of Beirut Medical CenterOTHER | 1 | May 14, 2026 | clinicaltrials |
| NCT07454863 | A Mass Balance Study of DZD8586 in Healthy Male Participants (TAI-SHAN15) | completed | Phase 1 | 6 | Dizal PharmaceuticalsINDUSTRY | 1 | May 14, 2026 | clinicaltrials |
| NCT01009840 | IV Busulfan Plus Bortezomib Conditioning Regimen for Second Autologous Stem Cell Transplant in Multiple Myeloma Patients | completed | Phase 2 | 30 | Otsuka Pharmaceutical Development & Commercialization, Inc.INDUSTRY | 2 | May 13, 2026 | clinicaltrials |
| NCT02362035 | ACP-196 (Acalabrutinib) in Combination With Pembrolizumab, for Treatment of Hematologic Malignancies(KEYNOTE145) | completed | Phase 1 / Phase 2 | 161 | Acerta Pharma BVINDUSTRY | 1 | May 13, 2026 | clinicaltrials |
| NCT04093596 | Safety and Efficacy of ALLO-715 BCMA Allogenic CAR T Cells in in Adults With Relapsed or Refractory Multiple Myeloma (UNIVERSAL)(UNIVERSAL) | completed | Phase 1 | 73 | Allogene TherapeuticsINDUSTRY | 1 | May 13, 2026 | clinicaltrials |
| NCT04687761 | Clinical Trial to Assess the Safety and Tolerability of the Combination of Low-dose Cytarabine or Azacitidine Plus Venetoclax and Quizartinib in Newly Diagnosed AML Patients Aged Equal or More Than 60 Years Old | completed | Phase 1 / Phase 2 | 113 | PETHEMA FoundationOTHER | 1 | May 13, 2026 | clinicaltrials |
| NCT05169658 | Mosunetuzumab With or Without Polatuzumab Vedotin and Obinutuzumab for the Treatment of Untreated Indolent B-Cell Non-Hodgkin Lymphoma | completed | Phase 2 | 42 | University of WashingtonOTHER | 1 | May 13, 2026 | clinicaltrials |
| NCT05673460 | A Clinical Study of Nemtabrutinib in Japanese Participants With Hematological Malignancies (MK-1026-002) | completed | Phase 1 | 7 | Merck Sharp & Dohme LLCINDUSTRY | 1 | May 13, 2026 | clinicaltrials |
| NCT07585331 | Towards Effective, Patient-tailored Anti-plasma Cell Therapies in AL Amyloidosis: Predicting Drug Response and Overcoming Drug Resistance | completed | — | 250 | Fondazione IRCCS Policlinico San Matteo di PaviaOTHER | 1 | May 13, 2026 | clinicaltrials |
| NCT01208896 | Allogeneic Hematopoietic Stem Cell Transplantation After Reduced-intensity Conditioning for Relapsed Follicular Lymphoma(RITALLO) | completed | Phase 2 | 32 | University Hospital, BordeauxOTHER | 1 | May 12, 2026 | clinicaltrials |
| NCT03891914 | Prospective Comparison of 18F-choline PET/CT and 18F-FDG PET/CT in the Initial Work-up of Multiple Myeloma(MYELOCHOL) | completed | Phase 3 | 20 | University Hospital, BordeauxOTHER | 1 | May 12, 2026 | clinicaltrials |
| NCT04731844 | Curcumin and Piperine in Patients on Surveillance for Monoclonal Gammopathy, Smoldering Myeloma or Prostate Cancer | completed | Phase 2 | 30 | University of RochesterOTHER | 1 | May 12, 2026 | clinicaltrials |
| NCT03934684 | Study to Evaluate Safety Tolerability & Efficacy of Kyprolis (Carfilzomib) in Relapsed or Refractory Multiple Myeloma | completed | Phase 4 | 101 | AmgenINDUSTRY | 1 | May 11, 2026 | clinicaltrials |
| NCT05335369 | A Patient-Centered Communication Tool (UR-GOAL) Versus Usual Care for Older Patients With Acute Myeloid Leukemia, Their Caregivers, and Their Oncologists(UR-GOAL 2) | completed | N/A | 161 | University of RochesterOTHER | 1 | May 11, 2026 | clinicaltrials |
| NCT03413800 | Len/Dex/DLI in Relapsed Multiple Myeloma After Allogeneic Stem Cell Transplant | completed | Phase 2 | 10 | Ciusss de L'Est de l'Île de MontréalOTHER | 1 | May 8, 2026 | clinicaltrials |
| NCT05490121 | RISE With Residents(RISE Residents) | completed | N/A | 84 | McMaster UniversityOTHER | 1 | May 8, 2026 | clinicaltrials |
| NCT05754814 | SUper-Resolution Ultrasound Imaging of Erythrocytes (SURE) in Normal and Malignant Lymph Nodes | completed | — | 20 | Rigshospitalet, DenmarkOTHER | 1 | May 8, 2026 | clinicaltrials |
| NCT06322927 | PatIent exPeRiences and prEFerence of trEatment foR Multiple Myeloma(iPREFER) | completed | — | 9 | The Christie NHS Foundation TrustOTHER | 1 | May 8, 2026 | clinicaltrials |
| NCT02300961 | Feasibility Neurocognitive Outcome After Transplant | completed | N/A | 17 | Stanford UniversityOTHER | 1 | May 7, 2026 | clinicaltrials |
| NCT03927105 | Nivolumab and the Antagonistic CSF-1R Monoclonal Antibody Cabiralizumab (BMS-986227) in Patients With Relapsed/Refractory Peripheral T Cell Lymphoma | completed | Phase 2 | 4 | University of Michigan Rogel Cancer CenterOTHER | 1 | May 7, 2026 | clinicaltrials |
| NCT05155709 | A Study of Siremadlin in Combination With Venetoclax Plus Azacitidine in Adult Participants With Acute Myeloid Leukemia (AML) Who Are Ineligible for Chemotherapy. | completed | Phase 1 | 14 | Novartis PharmaceuticalsINDUSTRY | 7 | May 7, 2026 | clinicaltrials |
| NCT05558696 | A Study of Bomedemstat (IMG-7289/MK-3543) in Participants With Polycythemia Vera (IMG-7289-CTP-203/MK-3543-004) | completed | Phase 2 | 20 | Imago BioSciences, Inc., a subsidiary of Merck & Co., Inc., (Rahway, New Jersey USA)INDUSTRY | 3 | May 7, 2026 | clinicaltrials |
| NCT04745910 | Pegloticase for the Reduction of Uric Acid in Patients With Tumor Lysis Syndrome | completed | Phase 4 | 10 | M.D. Anderson Cancer CenterOTHER | 1 | May 6, 2026 | clinicaltrials |
| NCT05532722 | ABC008 in Subjects With T-cell Large Granular Lymphocytic Leukemia (T-LGLL) | completed | Phase 1 / Phase 2 | 21 | Abcuro, Inc.INDUSTRY | 1 | May 6, 2026 | clinicaltrials |
| NCT05750706 | Incidence of Invasive Fungal Infections Among Patients With Acute Lymphoblastic Leukemia Ph-negative(SEIFEM) | completed | — | 150 | Fondazione Policlinico Universitario Agostino Gemelli IRCCSOTHER | 1 | May 6, 2026 | clinicaltrials |
| NCT03477539 | Daratumumab in Treating Transplant-Eligible Patients With Multiple Myeloma | completed | Phase 2 | 49 | Mayo ClinicOTHER | 1 | May 5, 2026 | clinicaltrials |
| NCT03580564 | An Open, Multicenter Phase II Study to Evaluate the Safety and Efficacy of KL-A167 Injection in Relapsed or Refractory Classical Hodgkin's Lymphoma | completed | Phase 2 | 109 | Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.INDUSTRY | 1 | May 5, 2026 | clinicaltrials |
| NCT05064358 | Study to Investigate Alternative Dosing Regimens of Belantamab Mafodotin in Participants With Relapsed or Refractory Multiple Myeloma(DREAMM 14) | completed | Phase 2 | 177 | GlaxoSmithKlineINDUSTRY | 18 | May 5, 2026 | clinicaltrials |
| NCT05441514 | Enasidenib in Combination With Cobimetinib for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia | completed | Phase 1 | 3 | City of Hope Medical CenterOTHER | 1 | May 5, 2026 | clinicaltrials |
| NCT00641381 | Carmustine, Etoposide, Cyclophosphamide, and Stem Cell Transplant in Treating Patients With HIV-Associated Lymphoma | completed | Phase 1 | 25 | City of Hope Medical CenterOTHER | 1 | May 4, 2026 | clinicaltrials |
| NCT03035331 | Dendritic Cell Therapy, Cryosurgery, and Pembrolizumab in Treating Patients With Non-Hodgkin Lymphoma | completed | Phase 1 / Phase 2 | 11 | Mayo ClinicOTHER | 1 | May 4, 2026 | clinicaltrials |
| NCT04083534 | First In Human (FIH) Study of REGN5459 in Adult Patients With Relapsed or Refractory Multiple Myeloma (MM) | completed | Phase 1 / Phase 2 | 43 | Regeneron PharmaceuticalsINDUSTRY | 1 | May 4, 2026 | clinicaltrials |
| NCT04509765 | A Phase II Single-arm Study of Total Body Irradiation With Linac Based VMAT and IGRT | completed | N/A | 36 | NYU Langone HealthOTHER | 1 | May 4, 2026 | clinicaltrials |
| NCT04636255 | Physical Capacity in Hodgkin Lymphoma Survivors | completed | N/A | 40 | University of Sao Paulo General HospitalOTHER | 1 | May 4, 2026 | clinicaltrials |
| NCT04167917 | NTX-301 in MDS/AML | completed | Phase 1 | 22 | University of Alabama at BirminghamOTHER | 1 | May 1, 2026 | clinicaltrials |
| NCT05517265 | Acalabrutinib in Patients With Chronic Lymphocytic Leukemia With Direct Oral Anticoagulation (CICERO)(CICERO) | completed | — | 45 | iOMEDICO AGINDUSTRY | 1 | May 1, 2026 | clinicaltrials |
| NCT01231412 | Graft-Versus-Host Disease Prophylaxis in Treating Patients With Hematologic Malignancies Undergoing Unrelated Donor Peripheral Blood Stem Cell Transplant | completed | Phase 3 | 174 | Fred Hutchinson Cancer CenterOTHER | 3 | Apr 30, 2026 | clinicaltrials |
| NCT00558519 | Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Lymphoblastic Leukemia | completed | Phase 2 | 318 | Alliance for Clinical Trials in OncologyOTHER | 0 | Apr 29, 2026 | clinicaltrials |
| NCT03902184 | IPH4102/Lacutamab Alone or in Combination With Chemotherapy in Patients With Advanced T Cell Lymphoma(TELLOMAK) | completed | Phase 2 | 170 | Innate PharmaINDUSTRY | 8 | Apr 29, 2026 | clinicaltrials |
Data updated 23 days agoSource updated May 15, 2026source: clinicaltrials